How long tirzepatide stays in your system — and why it matters

What 'half-life of five days' means in plain terms

A half-life is the time it takes for your body to reduce the concentration of a medicine by half. With tirzepatide at approximately five days, after one week about 75% of a single dose remains, and after five weeks roughly 97% has cleared. That is why clinicians, including the prescribers who review consultations at nume, refer to five weeks as the practical washout period when stopping is being considered.

This also explains the titration schedule. The treatment begins at 2.5 mg for the first four weeks, not because 2.5 mg drives significant weight loss on its own, but because the body needs time to adapt as concentrations build. By the time a dose increase lands on top of a stable baseline, the prescriber can tell more cleanly whether side effects are genuine responses or just the normal settling-in period. Steady-state levels are reached after four to five weeks of once-weekly dosing at a given dose, which is why titration steps are at least four weeks apart.

One more practical note: because tirzepatide accumulates, skipping a single injection does not wipe out your therapeutic levels overnight. The NHS advises taking the missed dose as soon as possible within a few days, then returning to your regular schedule. If more than four days have passed, skip that dose and carry on as normal, though the Patient Information Leaflet and your prescriber's guidance always take precedence over any general rule.

What the long half-life means if you stop treatment

Stopping tirzepatide is a real decision many people face: cost, a planned pregnancy, surgery, or a period abroad. Because the medicine stays active for weeks rather than days, the appetite-suppressing effect does not vanish overnight. Most people notice hunger returning gradually over the first two to four weeks after the final dose. Weight can begin to creep back during that window, which is why the guidance from NHS England on weight-management medicines consistently frames these treatments as long-term tools alongside lifestyle changes, not short courses.

If you are planning to conceive, the MHRA advises stopping tirzepatide and allowing an appropriate washout period before trying; if you want to understand how long tirzepatide stays in your system and why that shapes the clearance recommendation, the five-week timeline is explained in full there. Pregnancy and breastfeeding are clear contraindications, and women of childbearing age using oral contraceptives need to add a non-oral method for the first four weeks of treatment and for four weeks after each dose increase, because absorption of the pill can be reduced by the gastric-slowing effect of tirzepatide.

If surgery is planned, anaesthetists need to know. NHS England's guidance on weight-management injections specifically flags that the delayed gastric emptying caused by GLP-1 and GIP receptor agonists raises aspiration risk under general anaesthesia. Some surgical teams now request a pause of several weeks before elective procedures, and if you are wondering how long Mounjaro remains in your system after stopping, that page explains in detail why a multi-week window is requested rather than just a few days.

Restarting after a break, what to expect

People restart for many reasons: finances settle, a holiday ends, post-operative recovery is complete. The question our prescribers hear regularly is whether restarting means going back to 2.5 mg or resuming at the previous dose. The answer depends on how long the break was. A short gap of a week or two typically allows resuming where you left off, guided by the prescriber's judgement. A longer break, especially beyond five weeks, often means restarting the titration from the beginning to give the gut time to readjust.

At nume (sorry, at our pharmacy) every repeat order, including restarts, goes through clinical review before dispensing. That review matters more on a restart than almost any other point, because returning at too high a dose is the single most common cause of the severe nausea that makes people give up on treatment altogether. If you paused over a bank holiday or waiting for payday, that is a very normal pattern, and the clinical review exists precisely to catch those situations before the pen is sent out.

You can read more about how quickly tirzepatide begins to have an effect after restarting and what the realistic timeline looks like. For a fuller picture of cost and treatment options side by side, the treatment overview page is a useful starting point before any consultation.

Storage, travel and the five-week tail

Tirzepatide's duration in the body is a separate question from its shelf life outside the body, though both matter. Each KwikPen must be stored in the fridge at 2–8°C; the exact room-temperature window once removed is stated in the Patient Information Leaflet, and the NHS tirzepatide medicines page summarises it clearly alongside the full side-effect profile. Never estimate that window yourself, the leaflet figure is precise for a reason.

For travel, especially anything longer than a weekend, planning around the once-weekly dosing schedule and the five-week washout matters if you are thinking of pausing. One missed injection will not collapse your therapeutic levels, but two or three consecutive missed doses, especially at lower doses early in titration, effectively restarts the accumulation curve. Travelling just before a planned dose increase is worth discussing with your prescriber in advance. The general FAQs cover some of these logistics, and the support team is available seven days a week if a question comes up mid-trip.

Tirzepatide is a prescription-only medicine. Its pharmacokinetic profile is well understood from the SURMOUNT clinical programme, but how it behaves in your specific circumstances (other medicines, kidney function, body composition) is something only a prescriber can assess. The NICE appraisal of tirzepatide (TA1026) outlines the clinical framework; the individual decision is made one-to-one.